带量采购政策对某院心血管药物原研药和仿制药使用影响

doi:10.3969/j.issn.1006-5253.2022.05.013

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (4502 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Guide

Abstract

Objective To analyze the impact of volume-based purchasing policy on the use of branded and generic cardiovascular drugs in a tertiary hospital, and to provide reference for the further use of generic drugs and the implementation of drug-related policies.Methods Object drugs of the hospital were selected to analyze the number and proportion of branded and generic cardiovascular drugs, consumption sum and proportion, defined daily doses (DDDs), defined daily dose cost (DDDc), the substitution rate of generic drugs, and actual cost savings before and after the implementation of quantitative purchasing policy.Results After the implementation of volume-based purchasing policy, there is no impact on the unit price of branded cardiovascular drugs in the sample hospital, while the unit price of generic drugs show a downward trend. Compared to the pre-policy period, the overall use of branded cardiovascular drugs increased and accounted for a smaller share of the common use, while generics did the opposite. Overall sales of branded drugs declined but increased as a percentage of common sales, while overall sales of generics declined but decreased as a percentage of common sales. DDDs of the object drugs basically increased overall and DDDc of both decreased. The substitution rate of generic drugs rose, with actual savings of 3.075 6 million yuan.Conclusion After the implementation of volume-based purchasing policy in the sample hospital, the drug burden of some patients was effectively reduced and the drug cost was saved.

Key words： volume-based purchasing policy cardiovascular drug branded drug generic drug

Received: 26 April 2022

PACS:

Fund:

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Qingtong
	Wan Jun
	Jiao Shuguang
	Liu Guocheng
	Zhao Shuang
	Wang Xiangyu

Cite this article:

Li Qingtong,Wan Jun,Jiao Shuguang, et al. Impact of volume-based purchasing policy on the use of branded and generic cardiovascular drugs in a hospital[J]. journal1, 2022, 29(5): 377-382.

URL:

http://manu58.magtech.com.cn/Jwk_zgyytj/EN/10.3969/j.issn.1006-5253.2022.05.013 OR http://manu58.magtech.com.cn/Jwk_zgyytj/EN/Y2022/V29/I5/377

［1］张苏.推进仿制药创新破解医保开支难题［N］．中国证券报，2020-10-12(A03). 

［2］国务院办公厅.国务院办公厅关于印发国家组织药品集中采购和使用试点方案的通知［EB/OL］.(2019-01-17)［2022-04-16］.http://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm.

［3］国家医疗保障局，国家工业和信息化部，国家财政部，等. 国家医疗保障局等九部门关于国家组织药品集中采购和使用试点扩大区域范围实施意见［EB/OL］.(2019-09-30)［2022-04-16］.http://www.nhsa.gov.cn/art/2019/9/30/art_37_1817.html.

［4］健康中国行动推进委员会.健康中国行动(2019—2030年)［EB/OL］.(2019-07-15)［2022-04-16］.http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.

［5］中国心血管健康与疾病报告编写组．中国心血管健康与疾病报告2020概要［J］．中国循环杂志，2021，36(6)：521-545．DOI:10.3969/j.issn.1000-3614.2021.06.001. 

［6］王燕逍翔，白建军，宇传华．基于全球视角的中国心血管病疾病负担现状及趋势［J］．公共卫生与预防医学，2021，32(6)：6-11． DOI:10.3969/j.issn.1006-2483.2021.06.002. 

［7］尚迪，邹芳．2018—2020年某三级医院急性心肌梗死患者住院费用影响因素分析［J］．中国医院统计，2022，29(1)：47-50．DOI:10.3969/j.issn.1006-5253.2022.01.010. 

［8］World Health Organization. Guidelines for ATC classification and DDD assignment 2021［S/QL］．(2020-12-17)［2022-04-16］. https://www.whocc.no/filearchive/publications/2021 guidelines web.pdf.

［9］吴红，李歆，陈敬，等．带量采购政策对苏北地区5家公立医院原研药和仿制药临床使用的影响［J］．药学与临床研究，2021，29(3)：237-240．DOI:10.13664/j.cnki.pcr.2021.03.020.

［10］何江江，唐密，丛鹂萱，等．国家组织药品集中采购和使用试点对临床用药管理与使用的影响［J］．中国卫生资源，2021，24(1)：29-31．DOI:10.13688/j.cnki.chr.2021.200802.

［11］黄仲义，李光慧．仿制药质量一致性评价及有关建议［J］．上海医药，2019，40(7)：3-5．DOI:10.3969/j.issn.1006-1533.2019.07.002.

［12］中国政府网. 国务院办公厅印发《关于开展仿制药质量和疗效一致性评价的意见》［EB/OL］.(2016-03-05)［2022-04-16］. http://www.gov.cn/xinwen/2016-03/05/content_5049517.htm.

［13］王虎峰．中国医改周期与管理创新［M］．北京：人民卫生出版社，2019． 

［14］戴国琳，马浩，张可，等．我国仿制药发展现状及对策研究［J］．中国医药科学，2022，12(2)：185-188．DOI:10.3969/j.issn.2095-0616.2022.02.048. 

［15］陈志东，张毅，张勤．我国仿制药质量和疗效一致性评价后应关注的几个问题［J］．上海医药，2019，40(17)：56-59．DOI:10.3969/j.issn.1006-1533.2019.17.017. 

［16］周菁菁，谈在祥．我国药品带量采购政策实施效果研究：以S医院为例［J］．卫生经济研究，2021，38(10)：52-55．DOI:10.14055/j.cnki.33-1056/f.2021.10.012. 

［17］王永佩．史密斯模型下药品集中采购政策执行问题研究：以河南省为例［D］．新乡：新乡医学院，2020． 

［18］杜雪，马珺，黎雯霞．药品带量采购存在的问题与对策分析［J］．卫生经济研究，2020，37(8)：42-44．DOI:10.14055/j.cnki.33-1056/f.2020.08.010. 

［19］国家卫生健康委办公厅．关于做好国家组织药品集中采购中选药品临床配备使用工作的通知［EB/OL］.(2019-12-19)［2022-04-16］.http://www.gov.cn/xinwen/2019-12/19/content_5462458.htm.

［20］胡善联．价格、用量和结构要三管齐下［J］．中国卫生，2020(5)：56-57．DOI:10.15973/j.cnki.cn11-3708/d.2020.05.019. 

［21］于竞进．促进药品回归临床价值［J］．中国卫生，2020(2)：87-88．DOI:10.15973/j.cnki.cn11-3708/d.2020.02.041. 

［22］中国政府网. 李克强: 进一步推进药品集中采购和使用［EB/OL］.(2019-11-22)［2022-04-16］.http://www.gov.cn/premier/2019-11/22/content_5454499.htm.

［23］郝梦娇，王贺，罗宁泰，等．国家集采常态化制度逐渐成熟明朗［J］．中国卫生，2020(6)：79-81．DOI:10.15973/j.cnki.cn11-3708/d.2020.06.023. 